BioPharmSignal logoBioPharmSignal

Biotech News

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026

Design Therapeutics (DSGN)Design TherapeuticsClinical readout

CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with

Related news

DSGNDesign Therapeutics2026-05-18 11:00 EST

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

DSGNDesign Therapeutics2025-06-04 11:00 EST

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

View all latest news

Design Therapeutics

GeneTAC Platform Design Therapeutics develops GeneTAC small molecules that bind genomic repeat sequences and modulate transcription. The platform is designed either to increase expression of a deficient gene or reduce expression of a toxic mutant gene. DT-216P2 DT-216P2 is being developed for Friedreich ataxia and is designed to increase...

Recent company news

DSGNDesign Therapeutics2026-08-03 12:00 EST

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

DSGNDesign Therapeutics2026-06-30 12:00 EST

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

DSGNDesign Therapeutics2026-05-28 12:00 EST

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

DSGNDesign Therapeutics2026-05-18 11:00 EST

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

DSGNDesign Therapeutics2026-05-17 20:00 EST

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026

Stock data

Close
14.99 USD
Market cap
635.19M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States